National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

oral sodium phenylbutyrate
An orally active derivative of the short-chain fatty acid butyrate with potential antineoplastic activity. 4-Phenylbutyrate inhibits histone deacetylase, resulting in cell cycle gene expression modulation, reduced cell proliferation, increased cell differentiation, and apoptosis. This agent also initiates fragmentation of genomic DNA, resulting in decreased DNA synthesis and the inhibition of tumor cell migration and invasion. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:oral JAK inhibitor INCB18424, oral JAK2 inhibitor SB1518, oral microencapsulated diindolylmethane, oral milataxel, oral picoplatin
Next:oral topotecan hydrochloride, Oralet, Oramorph, Oramorph SR, Orasone

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov